NEW YORK (GenomeWeb News) - The National Cancer Institute has renewed and extended a software licensing agreement with Genomatix Software’s US subsidiary, the Munich, Germany-based company said today.
Genomatix said the agreement marks the fourth consecutive year of the license with NCI.
Genomatix opened its US subsidiary earlier this year.
“We are extremely pleased with our progress in putting the US company on its feet, and the renewal with NCI/NIH is a huge step in firmly establishing our presence here”, said Peter Grant, CEO of the US company, in a statement.
Specific terms of the agreement were not released.